Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Chronic Spontaneous Urticaria Market Expected To Grow In Terms Of Size?

The market size for chronic spontaneous urticaria has seen a robust growth in the past few years. The market is expected to rise from a value of $2.06 billion in 2024 to about $2.23 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. Factors such as advancements in diagnostic tools, increased awareness in the healthcare sector, patient support and advocacy groups, ongoing research and clinical trials for new treatment methods, and heightened healthcare spending have contributed to the growth seen in the historic period.

Expectations are high for robust growth in the chronic spontaneous urticaria market in the coming years, with projections to reach $3.01 billion by 2029, reflecting a compound annual growth rate (CAGR) of 7.9%. The surge expected in the forecast period is due to several factors including a rise in diagnosed CSU cases, an expanding patient base, improved healthcare facilities, a conducive regulatory environment favoring patient-oriented care models, and prosperity in emerging markets. The forecast period also unveils key trends like breakthroughs in technology, enhancements in biological therapy, advancements in personalized medicine, digital health and telemedicine, refined diagnostic tools, the rise of AI and machine learning, and an increase in drug approvals and introductions.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which Key Factors Are Fueling Growth In The Chronic Spontaneous Urticaria Market?

The surge in alcohol intake is expected to drive the expansion of the chronic spontaneous urticaria market. Various factors such as societal pressures, stress, marketing, cost-effectiveness, and accessibility contribute to this increased alcohol consumption. An increase in alcohol intake can considerably worsen chronic spontaneous urticaria symptoms in some people, leading to a rise in hives and skin swelling. For illustration, as reported by rehabs.UK, a UK-based company offering addiction recovery support and counselling services, in February 2024, 55% of men and 41% of women were reported to consume alcohol weekly. Furthermore, 8% of men and 5% of women were reported to consume alcohol nearly every day. Between 2021 and 2022, 342,795 instances of hospital admission were solely due to alcohol-related issues, equating to a rate of 626 admissions per 100,000 individuals. Consequently, the escalating consumption of alcohol is fuelling the growth of the chronic spontaneous urticaria market.

How Is The Chronic Spontaneous Urticaria Market Categorized Across Applications And Types?

The chronic spontaneous urticariamarket covered in this report is segmented –

1) By Treatment: Medication; Phototherapy; Other Treatments

2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration

3) By Diagnosis: Physical Examination; Blood Test; Allergy Test; Other Diagnosis

4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Medication: Antihistamines; Leukotriene Receptor Antagonists; Monoclonal Antibodies; Immunosuppressants; Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy; UVA Phototherapy; Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies; Dietary Modifications; Psychotherapy (for Stress-Related Triggers)

How Are Industry Trends Steering The Expansion Of The Chronic Spontaneous Urticaria Market?

Key players in the chronic spontaneous urticaria market are advancing the progression of next-gen Briquilimab (JSP191), with the goal of heightening treatment effectiveness and minimizing dosing frequencies. This next-generation Briquilimab is a monoclonal antibody that’s manipulated to concentrate on and eradicate particular immune cells, specifically focusing on CD47, associated with chronic spontaneous urticaria. For instance, Jasper Therapeutics Inc., a clinical-stage biotechnology firm based in the US, stated in November 2023 that it initiated dosing for the inaugural patient in a Phase 1b/2a clinical research of Briquilimab for chronic spontaneous urticaria (CSU). This milestone is vital in evaluating the safety and efficacy of this next-generation monoclonal antibody, which is targeting CD47, for combating this recurring hive and itching condition. The research has a goal to quantify how effectively Briquilimab can lessen symptoms and elevate life quality for CSU patients.

Which Firms Are Making The Biggest Impact In The Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Region Holds The Greatest Opportunity For Chronic Spontaneous Urticaria Market Expansion?

North America was the largest region in the chronic spontaneous urticaria market in 2024. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2025, By The Business Research Company

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model